The use of marijuana as medicine has been criticized largely for years. Marijuana, or cannabis, which is abused for all wrong reasons, is found to have some rare medicinal properties with the potential to cure certain fatal health conditions. For the first time, FDA announced its approval of a marijuana-derived drug called Epidiolex, produced by GW Research Ltd. for treating epilepsy.
Cannabis contains a chemical called CBD (cannabidiol) which is highly effective in treating seizures, a condition of neurological disturbance that happens when nerve cells function abnormally. Unlike THC (Tetrahydrocannabinol) which is also cannabis constituent, CBD doesn’t produce psychoactive effects on consumption. After conducting several trials, FDA gave its green signal to CBD for the first time.
It is the first ever FDA-approved drug that contains a purified drug substance derived from cannabis. Marijuana can be now legally used to produce Epidilex to treat conditions like Lennox-Gastaut syndrome and Dravet syndrome. The medical acknowledgment of CBD is surely a great news for startups that target the compound for medicinal and consumer use.
It can undoubtedly cure certain neurological conditions but the question is about the misuse of the drug. Hence, the FDA is strict about its actions against illegal CBD products and provides recommendations to the Drug Enforcement Administration (DEA) regarding controls under Controlled substance Act.
Although the use of cannabis for substance abuse is a rampant issue, identifying its medicinal benefits has put cannabis usage on the right track!
Fujitsu Partners Oracle and SAP: To Accelerate Cloud Transformation and Leverage Multi-Cloud Solution